| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
SPS-4251 [PAP-1; SPS4251; 5-(4-Phenoxybutoxy)psoralen] is a novel and potent KCNA3 channel blocker (inhibitor of Kv1.3, voltage-gated K+ channel) with the potential to be used in treatment of multiple sclerosis.
| ln Vitro |
PAP-1 (2-100 nM; 30 minutes) suppresses CCR7-TEM cell proliferation with an IC50 of 10 nM [1].
|
|---|---|
| ln Vivo |
Lewis rats treated intraperitoneally with PAP-1 (0.3–3 mg/kg) three times a day for 48 hours are protected against delayed-type hypersensitivity (DTH) [1].
|
| Cell Assay |
Cell proliferation assay [1]
Cell Types: CCR7-TEM cells (anti-CD3 Ab stimulation) Tested Concentrations: 2, 10, 25, 100 nM Incubation Duration: 30 minutes Experimental Results: Inhibits the proliferation of CCR7-TEM cells, IC50 is 10 nM. |
| Animal Protocol |
Animal/Disease Models: 9 to 11 weeks old female Lewis rats [1] Usage and
Doses: intraperitoneal (ip) injection; 3 times a day for 48 hrs (hrs (hours)). Dosing: 0.3, 1, 3 mg/kg. Experimental Results: Dose-dependent inhibition of DTH response. |
| References |
[1]. Schmitz A, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70.
[2]. Pereira LE, et al. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood). 2007 Nov;232(10):1338-54. |
| Molecular Formula |
C21H18O5
|
|---|---|
| Molecular Weight |
350.37
|
| Exact Mass |
350.1154
|
| CAS # |
870653-45-5
|
| SMILES |
O(C([H])([H])C([H])([H])C([H])([H])C([H])([H])OC1C([H])=C([H])C([H])=C([H])C=1[H])C1=C2C([H])=C([H])C(=O)OC2=C([H])C2=C1C([H])=C([H])O2
|
| Synonyms |
SPS4251 SPS 4251 SPS-4251PAP-1SPS42515-(4-Phenoxybutoxy)psoralen
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~142.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.14 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8541 mL | 14.2706 mL | 28.5413 mL | |
| 5 mM | 0.5708 mL | 2.8541 mL | 5.7083 mL | |
| 10 mM | 0.2854 mL | 1.4271 mL | 2.8541 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
